Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of Loncastuximab Tesirine in Relapsed or Refractory DLBCL
2017-004288-11Phase 2Unknown
- Sponsor
- ADC Therapeutics
- Start
- Sep 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL), sponsored by ADC Therapeutics. Primary endpoint: Overall Response Rate. Status: unknown.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2017-004288-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004288-11.